StockNews.AI
BMY
Benzinga
13 hrs

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

1. BMY shares interim Phase 2 data on pumitamig for ES-SCLC. 2. 76.3% overall response rate and 100% disease control rate were achieved. 3. Median progression-free survival recorded was 6.8 months. 4. A Phase 3 trial is underway comparing treatments for lung cancer. 5. BMY stock is down 1.67%, reflecting market reactions.

3m saved
Insight
Article

FAQ

Why Bullish?

The strong response and safety data for pumitamig suggest significant potential, akin to past successes for BMY with similar drugs.

How important is it?

Positive clinical trial results can influence stock performance and investor sentiment significantly.

Why Long Term?

If the Phase 3 trial is successful, it could enhance BMY’s oncology portfolio, driving long-term growth.

Related Companies

Related News